The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab[S]

An elevated level of lipoprotein (a) [Lp(a)] is a risk factor for CVD. Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9, is reported to reduce Lp(a) levels. The relationship of Lp(a) reduction with apo(a) size polymorphism, phenotype, and dominance pattern and LDL c...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Byambaa Enkhmaa, Erdembileg Anuurad, Wei Zhang, Kun Yue, Ching-Shang Li, Lars Berglund
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2017-10-01
coleção:	Journal of Lipid Research
Assuntos:	lipoprotein (a) apolipoprotein (a) apolipoproteins clinical studies lipoproteins drug therapy/hypolipidemic drugs
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S0022227520335719
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!